Collegium Pharmaceutical Inc (NASDAQ:COLL) — Market Cap & Net Worth
Market Cap & Net Worth: Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc (NASDAQ:COLL) has a market capitalization of $690.38 Million ($690.38 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10636 globally and #2819 in its home market, demonstrating a -7.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Collegium Pharmaceutical Inc's stock price $21.84 by its total outstanding shares 31610976 (31.61 Million). Also see Collegium Pharmaceutical Inc total assets for a full breakdown of the balance sheet.
Collegium Pharmaceutical Inc Market Cap History: 2015 to 2026
Collegium Pharmaceutical Inc's market capitalization history from 2015 to 2026. Data shows growth from $869.30 Million to $690.38 Million (1.24% CAGR). Also see how efficiently does Collegium Pharmaceutical Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Collegium Pharmaceutical Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #300 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1096 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.04% | #173 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.07% | #518 of 602 |
Weight: Collegium Pharmaceutical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Collegium Pharmaceutical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Collegium Pharmaceutical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Collegium Pharmaceutical Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.43x
Collegium Pharmaceutical Inc's market cap is 1.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.09x
Collegium Pharmaceutical Inc's market cap is 13.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $492.18 Million | $1.71 Million | -$94.18 Million | 287.66x | N/A |
| 2017 | $583.54 Million | $28.48 Million | -$74.86 Million | 20.49x | N/A |
| 2018 | $542.76 Million | $280.41 Million | -$39.13 Million | 1.94x | N/A |
| 2019 | $650.55 Million | $296.70 Million | -$22.72 Million | 2.19x | N/A |
| 2020 | $633.17 Million | $310.02 Million | $26.75 Million | 2.04x | 23.67x |
| 2021 | $590.49 Million | $276.87 Million | $71.52 Million | 2.13x | 8.26x |
| 2022 | $733.37 Million | $463.93 Million | -$25.00 Million | 1.58x | N/A |
| 2023 | $972.99 Million | $566.77 Million | $48.16 Million | 1.72x | 20.21x |
| 2024 | $905.65 Million | $631.45 Million | $69.19 Million | 1.43x | 13.09x |
Competitor Companies of COLL by Market Capitalization
Companies near Collegium Pharmaceutical Inc in the global market cap rankings as of September 17, 2026. Review COLL tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Collegium Pharmaceutical Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Collegium Pharmaceutical Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Collegium Pharmaceutical Inc's market cap moved from $869.30 Million to $ 690.38 Million, with a yearly change of 1.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $690.38 Million | -52.83% |
| 2025 | $1.46 Billion | +61.61% |
| 2024 | $905.65 Million | -6.92% |
| 2023 | $972.99 Million | +32.67% |
| 2022 | $733.37 Million | +24.20% |
| 2021 | $590.49 Million | -6.74% |
| 2020 | $633.17 Million | -2.67% |
| 2019 | $650.55 Million | +19.86% |
| 2018 | $542.76 Million | -6.99% |
| 2017 | $583.54 Million | +18.56% |
| 2016 | $492.18 Million | -43.38% |
| 2015 | $869.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Collegium Pharmaceutical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $690.38 Million USD |
| MoneyControl | $690.38 Million USD |
| MarketWatch | $690.38 Million USD |
| marketcap.company | $690.38 Million USD |
| Reuters | $690.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more